Once considered “undruggable,” RAS has become an important frontier in precision oncology. The development of direct KRAS G12C inhibitors established a foundation for a broader wave of therapies targeting additional mutations, active-state RAS, and multiple RAS variants. These approaches are expanding the development landscape across pancreatic, non-small-cell lung, and colorectal cancers

In the October 2026 edition of Octavus Insights Corner, we examine how advances in RAS biology are translating into clinical evidence, competitive positioning, and commercial opportunity. The analysis explores daraxonrasib and Revolution Medicines’ broader portfolio alongside emerging inhibitors, protein degraders, combination regimens, and alternative delivery approaches. It also considers the questions that will shape future differentiation: durability of benefit, tolerability, resistance, patient selection, and expansion into earlier treatment settings.